INFeD IS THE ONLY
LOW-MOLECULAR-WEIGHT IRON DEXTRAN
AVAILABLE ON THE MARKET
IMPORTANT SAFETY INFORMATION & USE: WARNING: RISK FOR ANAPHYLACTIC-TYPE REACTIONS. Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during INFeD administration.
Low-molecular-weight iron dextran
RESTORE AND REPLENISH WITH INFeD
INFeD® (iron dextran injection) is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron.
A LEGACY OF BALANCE
INFeD IS THE ONLY
LOW-MOLECULAR-WEIGHT IRON DEXTRAN
AVAILABLE ON THE MARKET
INFeD HAS BEEN
FDA APPROVED FOR DECADES
TO TREAT IRON DEFICIENCY*
COMMITMENT TO
PRODUCT QUALITY
AND SAFETY
*INFeD has been FDA approved since 1974 for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or an unsatisfactory response to oral iron.8
HOW INFeD WORKS TO REPLENISH IRON STORES AND TREAT ID AND IDA
INFeD is absorbed from the injection site into the capillaries and the lymphatic system10
Iron dextran in circulation is taken up into the reticuloendothelial system via endocytosis and metabolized in lysosomes, resulting in the release of ferrous iron (Fe[2+])10
Released Fe(2+) is stored as Fe-ferritin or transported into the blood via ferroportin10
Once in the blood, Fe(2+) is oxidized to ferric iron (Fe[3+]), bound to transferrin, and transported throughout the body, thereby restoring depleted iron stores and hemoglobin10
Changes in serum ferritin levels represent the changes in calculated cellular non-heme iron levels. After administration of iron
dextran, evidence of a therapeutic response can be seen as an increase in the reticulocyte count.8
Prior to the first INFeD therapeutic dose, administer a test dose. For specific testing instructions for both intramuscular and intravenous use, visit Dosing and Administration page.
INFeD IS WIDELY AVAILABLE ON COMMERCIAL, MEDICARE PART D AND MEDICAID INSURANCE PLANS.*
INFeD IS WIDELY AVAILABLE ON COMMERCIAL, MEDICARE PART D AND MEDICAID INSURANCE PLANS.*
*MMIT data as of May 2023. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurers. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
INFeD® (iron dextran injection) is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron.
Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection.
These are not all the possible side effects of INFeD.
INFeD is not recommended for use in infants under 4 months of age.
US-IFD-230006
Please see full Prescribing Information, including Boxed Warning